|
|
|
|
|
|
A specialty materials maker extended its dividend-growth streak to 16 years this week. The stock has cooled off from its high just as Q3 approaches, and I think you'll want to see this one.
|
| |
|
| |
|
|
|
Meet the Pick
Avient Corporation (NYSE: AVNT). Cleveland-based. Specialty materials. Market cap around $3.8 billion. Shares are up more than 25% this year but have cooled about 11% from their 52-week high over the past month.
Avient makes polymer colorants, additives, specialty engineered materials, and inks. The stuff shows up inside packaging, consumer goods, car parts, and medical devices.
Boring on the surface. Steady underneath. And on Tuesday, the board handed you its 16th straight annual dividend hike.
Tax Strategy (Sponsored)
Capital gains taxes can take a bigger bite out of your profits than expected.
Fortunately, some deductions may help reduce the impact — including:
Investment-related expenses
Certain real estate selling costs
Because rules and eligibility vary, many investors turn to fiduciary financial advisors for guidance.
Find an Advisor Match.
*This is not an offer to buy or sell any security or interest. All investing involves risk, including loss of principal. Working with an adviser may come with potential downsides such as payment of fees (which will reduce returns). Past performance is not a guarantee of future results. There are no guarantees that working with an adviser will yield positive returns. The existence of a fiduciary duty does not prevent the rise of potential conflicts of interest.
We do not manage client funds or hold custody of assets, we help users connect with relevant financial advisors.
The Boring Business Doing the Interesting Work
Here's what you're really buying when you buy Avient: formulation expertise. They don't make the plastic.
They make the thing that gives the plastic its color, its UV resistance, its anti-microbial properties, its flame retardance. High-margin layer of the chain. Sits inside stuff you touch every day without a second thought.
Why does this matter now? Specialty chemicals just lived through two miserable years. Destocking, soft European demand, lumpy consumer-goods volumes, the works. The group got clobbered. Avient didn't escape.
But the business has already turned. On August 6, Avient beat Q2 estimates with adjusted EPS up 20% to $0.96 and a record 18.3% adjusted EBITDA margin, and it raised full-year guidance.
Tuesday's hike, from $0.275 to $0.2825 a quarter ($1.10 to $1.13 a year), tells you the board expects that strength to hold. Boards don't raise payouts into a deteriorating business. They hoard cash.
|
| |
|
| |
|
|
|
Why the Numbers Still Work
Avient runs asset-light compared to its upstream chemical peers. That matters a lot when raw material prices go on a joyride.
They've got pricing power on the formulation side, and they don't carry the capital intensity of a bulk producer. Through cycles, that's historically meant a more defensive margin profile you can lean on.
Scale check: at about $3.8 billion, Avient is a small-cap, and the stock trades at roughly 12 times forward earnings. Let end-market demand keep normalizing, and the operating leverage flows straight to the bottom line.
Action block: Build the position before Q3 lands on November 4, not after. The $39 to $42 range is your anchor. Any constructive guidance on 2027 margins could push the multiple higher.
Elite Picks (Sponsored)
This report focuses on a narrow group of stocks identified through a detailed screening process.
Analysts apply a combination of metrics to narrow down potential opportunities.
Past selections have shown strong momentum, but no outcomes are guaranteed.
The newest edition is now open for access.
Get the report now.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Where the Tailwinds Are Hiding
Three structural shifts are working in Avient's favor. The stock's run this year prices in some of that, but not all of it.
- Packaging demand recovery. CPG customers burned through excess inventory in 2025 and into early 2026. Reorders are firming up. Avient sells into every category that benefits.
- Healthcare specialty materials. Medical device makers need specific polymer formulations with regulatory traceability. Sticky revenue, higher margin, keeps growing.
- Transportation lightweighting. Automakers chasing weight reduction for emissions and EV range targets are swapping metal for specialty polymer compounds. Avient has real IP here.
None of this is pie-in-the-sky stuff. These are grinding, multi-year trends that show up in revenue a little at a time. The only question is whether you want the exposure before Q3 confirms the inflection, or after.
|
| |
|
| |
|
|
|
What the Fundamentals Actually Say
The core argument isn't that earnings are about to blow the doors off. It's that you're paying about 12 times forward earnings for a business that just posted record margins and raised guidance.
Here's the pattern you want to see going into Q3: stabilizing organic volumes, gross margin holding, and management reiterating or raising the 2026 adjusted EBITDA outlook.
Check those three boxes and the stock has room to run back toward its 52-week high near $47 without any heroic assumptions. The dividend raise tells you management has the cash to back it up.
Early Signals (Sponsored)
You assume you're locked out of Anthropic.
You're half right.
Pre-IPO shares are closed — no secondary platform, no early allocation.
The public side is different.
Good Morning Alerts' analyst identified 3 companies trading on regular exchanges with real ties to Anthropic's growth: two mega-caps holding billion-dollar stakes, and a smaller supplier in its critical path.
See the setup before the crowd arrives
*This ad is sent on behalf of Stable Financial Publishing, LLC, 1013 Centre Road Suite 403-D, Wilmington, DE 19805. Nothing here is investment, financial, legal, or tax advice, and it is not a recommendation or solicitation to buy or sell any security. Investing in IPOs and equities involves substantial risk, including loss of principal; past performance and projections do not guarantee future results. Valuation and timing figures are third-party reports and investor expectations, not company guidance. Privacy: https://guardian.pub/privacy-policy/ · Terms: https://guardian.pub/terms-of-service/
The Dividend You Are Actually Buying
Here's the part that matters most if you're building an income sleeve. Avient's new quarterly dividend of $0.2825 annualizes to $1.13. At today's price near $41, that works out to a yield of about 2.7%.
The headline yield isn't what makes this interesting. The trajectory is. Sixteen straight annual increases don't happen by accident. It's a cultural commitment. And it survived the pandemic, the 2022 input-cost spike, and the 2024-25 destocking slog.
The payout runs about a third of expected adjusted earnings, so the company can keep raising even if earnings stay flattish for a quarter or two. That's the kind of dividend you want in a portfolio built to compound.
Action block: If you want income today AND dividend growth over the next decade, this is the kind of name you accumulate on weakness and let it do its work. Reinvest the dividends and add on pullbacks toward $39.
What Could Blow This Up
Fair warning on the risks. A few actually matter.
European industrial demand is still soft, and Avient has meaningful exposure over there. If the ECB stays restrictive longer than expected, your 2027 top-line estimates get walked down.
Raw material volatility, specifically on specialty resins and pigments, can squeeze gross margins when the company can't pass costs through fast enough.
Auto end-markets are cyclical. Any sharper slowdown in global auto builds dings a chunk of the specialty engineered materials line you're counting on.
And the honest one. If Q3 disappoints, this stock doesn't have a mega-cap sponsorship base to catch the fall. Another 10 to 15 percent downside before buyers show up is entirely possible. That's why the entry zone matters. And why you size accordingly.
Putting It All Together
Avient isn't flashy. It won't double in a quarter. What you get is a 16-year dividend-growth story inside a specialty materials business that still trades at about 12 times forward earnings.
This week's hike is management's signal that fundamentals are better than the share price suggests. The setup into Q3 looks tight.
If you're building a dividend portfolio and you want names where the compounding has decades still to run, this one fits.
Enter on weakness. Let the dividend do the heavy lifting while the operating cycle turns. Treat the November 4 earnings print as the next catalyst. That's the trade.
Setup Scorecard
Entry Zone: $39 to $42
Target: $48 over 12 to 18 months as margins normalize
Stop Loss: Reassess if shares close below $36
Catalyst Timeline: Q3 2026 earnings on November 4, before the open; first payment at the new $0.2825 rate in early January 2027
Confidence Level: Medium. Thesis hinges on end-market normalization and a Q3 print confirming stabilization. Dividend durability is high. Price catalyst timing, less so.
That’s all for today’s edition of the Dividend Brief.
Thanks for reading, and if you have any feedback or dividend stocks you want me to take a look at, just reply to this email!
—Noah Zelvis
DividendBrief.com
